Spectrum Pharmaceuticals, Inc. received approval to market Levoleucovorin for Injection from the FDA following application submissions supported by data from BioScreen Testing Services, Inc.  
    
“We offer our sincere congratulations to Spectrum,” said Bradford Rope, president of BioScreen Testing Services. “BioScreen looks forward to a continuing partnership, providing release testing support during the manufacture of Levoleucovorin, as well as additional development support for the many drugs in Spectrum’s pipeline. BioScreen provides contract testing services to companies and has contributed data to support many submissions to the FDA.